MLYS
Mineralys Therapeutics
$27.21
+$0.50 (+1.87%)Jul 27, 2026
Key metrics
The numbers that frame MLYS today
- Market cap
- $2.24B
- P/E (TTM)
- -14.8
- EV / FCF
- -15.6
- ROIC
- -38.7%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $12.59
- 52wk High
- $47.65
Growth
Revenue and earnings trend for MLYS
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about MLYS
Is Mineralys Therapeutics a good buy?
No. Mineralys Therapeutics has poor quality and mixed momentum. The setup is weak overall. Growth looks strong, which supports the long-term business case, but that is not enough to offset the weak setup. We think Mineralys Therapeutics is selling at a high price.
What is the market capitalization of MLYS?
Mineralys Therapeutics's market capitalization is $2.24B.
What is the P/E ratio for MLYS stock?
Mineralys Therapeutics's current P/E ratio is -14.8.
What is the 52-week high for MLYS stock?
The 52-week high for Mineralys Therapeutics is $47.65. The current close of $27.21 is 42.9% below that high.
What is the 52-week low for MLYS stock?
The 52-week low for Mineralys Therapeutics is $12.59. The current close of $27.21 is 116.1% above that low.
Does MLYS stock pay dividends?
Mineralys Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for MLYS?
Mineralys Therapeutics's Debt / Equity ratio is 0.